Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
The incretin hormones are intestinal polypeptides that enhance postprandial insulin secretion. Gastric inhibitory polypeptide (GIP) was initially thought to regulate gastric acid secretion, whereas glucagon-like peptide-1 (GLP-1) was discovered as a result of a systematic search for intestinal insulinotropic products of proglucagon gene expression. The incretin effect is markedly impaired or absent in patients with type 2 diabetes because of decreased secretion of GLP-1 and a loss of the insulinotropic effects of GIP. Metabolic control can be restored or greatly improved by administration of exogenous GLP-1, but this peptide is almost immediately degraded by dipeptidyl peptidase IV (DPP-IV), and therefore has little clinical value. DPP-IV-resistant analogues (incretin mimetics) have been identified or developed, and inhibitors of DPP-IV have also proved effective in protecting endogenous GLP-1 (and GIP) from degradation. Both principles have been tested in clinical studies. The incretin mimetics, administered by sc injection, have demonstrated lasting improvement in HbA(1)c in patients insufficiently treated with conventional oral therapy, and their use has been associated with steady weight loss for up to 2 years. The DPP-IV inhibitors, given once or twice daily by mouth, also appear to provide lasting improvement in HbA(1)c, but are weight-neutral. The first incretin mimetic has reached the market in the US, and applications for approval of the first inhibitors are expected to be filed early in 2006.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The major effect of incretins is the potentiation of glucose-stimulated insulin secretion by pancreatic β-cells [14,15,16,17].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“controlled pivotal phase III studies involving 1,494 patients, in whom exenatide was given for 30 weeks as an add-on therapy to type 2 diabetic patients inadequately treated with sulfonylureas [68], metformin [69] or a combination of metformin and sulfonylureas [70].”
BackgroundGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“In addition, GLP-1 was shown to inhibit appetite and food intake, both in healthy individuals [36], and in patients with type 2 diabetes [37].”
BackgroundSelf-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Self-citationXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Research works printed but not linked: 4
- 26. Holst JJ, Orskov C, Schwartz TW, Buhl T, Baldissera F (1986) Proglucagon 78-107, a potent insulinotropic hormone from the lower small intestine. Diabetologia 29:549A (Abstract)
- 50. Larsen J, Jallad J, Damsbo P (1996) One-week continuous infusion of GLP-1(7-37) improves glycemic control in NIDDM. Diabetes 45:233A (Abstract)
- 54. Ehlers MRW, Roderick EH, Schneider RL, Kipnes MS (2002) Continuous subcutaneous infusion of recombinant GLP-1 for 7 days dose-dependently improved glycemic controls in type 2 diabetes. Diabetes 51:A579 (Abstract)
- 74. Nauck M, Hompesch M, Filipczak R et al (2004) Liraglutide as add-on to metformin in type 2 diabetes: significant improvement in glycaemic control with a reduction in body weight compared with glimepiride. Diabetologia 47:A281 (Abstract)
Cited by
Items 201–253 of 253
Martin, C. L. (2007) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721706298434 · Cited by 2
SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide
Shirakawa, J., & Terauchi, Y. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.01.35 · Cited by 2
Sitagliptin and metformin combination therapy for the treatment of Type 2 diabetes
Gallwitz, B. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.23 · Cited by 1
Molecular Biology of Gluco-Incretin Function
Klinger, S., & Thorens, B. (2008) · Springer eBooks · doi:10.1007/978-4-431-75452-7_16 · Cited by 1
Incretin based therapies: Do they hold their promise?
Holst, J. J. (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2012.00186.x · Cited by 1
Self-citationIncretin Mimetics in the Treatment of Type 2 Diabetes Mellitus
Holst, J. J. (2006) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2006.00.01.1g · Cited by 1
Self-citationIncretin for the continuing treatment of secondary failure to metformin in Type 2 diabetes
Gallwitz, B. (2013) · Diabetes Management · doi:10.2217/dmt.13.29 · Cited by 1
Progression of Treatment Strategies in Type 2 Diabetes
Holt, R. I. G. (2010) · US Endocrinology · doi:10.17925/use.2010.06.1.34 · Cited by 1
Pharmacotherapy for Weight Loss
Lutz, T. A., & Asarian, L. (2017) · Routledge eBooks · doi:10.1201/9781315120171-14 · Cited by 1
Managing Type 2 Diabetes Mellitus Across the Disease Spectrum
Schorr, A. B. (2014) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2014.087 · Cited by 1
Antu, K. A., & Raghu, K. G. (2013) · Dyuthi Digital Repository (Cochin University of Science and Technology) · Cited by 1
Antidiabetic Drugs other than Insulin
Bailey, C. J. (2008) · Springer eBooks · doi:10.1007/978-3-540-38918-7_109 · Cited by 1
Anwar, B., Nadine, S., Lafi, S. M. A., Shushan, B. I., & Suzan, S. (2011) · InTech eBooks · doi:10.5772/22092
Yu, Z., & Jin, T. (2008) · Science Foundation in China · doi:10.1088/1005-0841/16/2/003
Krentz, A. J., Heinemann, L., & Hompesch, M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_2
GLP 1 : effets biologiques et utilisation thérapeutique
Fagour, C. (2007) · Annales d Endocrinologie · doi:10.1016/j.ando.2007.01.017
Caraterização da distribuição relativa de células neuroendócrinas no jejuno-íleo
Guedes, T. A. P. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/8yfx-9c56
Whey protein: Effects on insulin secretion and intestinal health via intestinal peptides
Ney, D. M., & Boehler, C. J. (2011) · Nutrafoods · doi:10.1007/bf03223384
Dipeptidyl Peptidase-4 Inhibitors as Add-on Therapy to Metformin
Åhrén, B. (2007) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2007.00.02.60
Goulet, O., & Abboud, S. A. (2016) · Hamdan Medical Journal · doi:10.7707/hmj.705
McKie, G. L. (2018) · Scholars Commons (Wilfrid Laurier University)
Palma, J. P. (2019) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2019.05.000927
Takagi, S., Hirokawa, M., Nagashima, K., Higuchi, M., Kadota, K., Ishikawa, R., Sato, M., Miyauchi, A., Miyake, Y., & Haba, R. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej19-0501
Schürmann, A., & Joost, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_48
Incretin Enhancers, Incretinomimetics – from Therapeutic Concept to Clinical Application
Winkler, G. (2007) · Hungarian Medical Journal · doi:10.1556/oh-hmj.2007.28093
(2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32802e6d87
Current literature in diabetes
(2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.683
Joost, H., & Schürmann, A. (2008) · Springer eBooks · doi:10.1007/978-3-540-38918-7_48
Schürmann, A., & Joost, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-21573-6_48-1
Diabetes Mellitus: From Definition to Therapy
Ciaccio, M., Ciaccio, A. M., & Agnello, L. (2023) · Springer eBooks · doi:10.1007/978-3-031-24958-7_26
Biosensors for open and closed-loop glycemia control
Puginier, E. (2022) · theses.fr (ABES) · doi:10.70675/88dd4f85z595bz410dz8d74z82d2f2e32eca
ASYMETRYCZNE REAKCJE PERICYKLICZNE KATALIZOWANE KOMPLEKSAMI MAGNEZU
Czombik, A. M. (2022) · Wiadomości Chemiczne · doi:10.53584/wiadchem.2022.9.3
Editorial: The impact of GIP/GIPR on metabolic diseases: how the field is evolving
Habegger, K. M., Tomás, A., Chen, R., Harris, C., Roell, W. C., & Coşkun, T. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1710843
Septal Glucagon-like Peptide 1 Receptor Signalling in Neuroplasticity and Drug-induced Behaviour
Harasta, A. E. (2014) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/2591
Isidora, S., Parada, J., Cataldo, L. R., Galgani, J. E., Alberti, G., Labayen, I., & Santos, J. L. (2025) · Endocrine Connections · doi:10.1530/ec-25-0804
Potoczniak, G., Ślusarczyk, A., Szarszoń, K., Gawłowski, J., Lizak, W., Dzień, E., Kozłowski, H., Garstka, K., Dziadas, M., Hecel, A., et al. (2026) · Wiadomości Chemiczne · doi:10.53584/wiadchem.2026.02.22
Glucose Regulation of Dipeptidyl Peptidase IV(DPPIV) Production in Adipocytes
Das, S. (2015) · Institutional Repositories DataBase (IRDB)
Histoire des incrétines GLP-1/GIP – De l’hormone au médicament couteau-suisse
Portha, B. (2026) · Biologie Aujourd hui · doi:10.1051/jbio/2026005
Stereochemical engineering of GLP-1 blocks proteolysis while preserving its metal-binding core
Potoczniak, G., Dziadas, M., Witkowska, D., Figurski, P., Nowak, B., & Rowińska‐Żyrek, M. (2026) · Chemical Communications · doi:10.1039/d6cc04811k
BindingDB (2012) · UC San Diego · doi:10.7270/q2vh5prk
BindingDB Entry 50042111: Long-acting peptidomimetics based DPP-IV inhibitors.
BindingDB (2013) · UC San Diego · doi:10.7270/q2qz2c77
BindingDB (2012) · UC San Diego · doi:10.7270/q2t72ht6
BindingDB (2017) · UC San Diego · doi:10.7270/q208675s
Effect of Opuntia humifusa on key enzymes of glycemic parameters and diabetic male mice
Choi, J.-H., Ryu, S.-J., & 김세웅 (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107579
The role of a nurse-led vascular risk reduction clinic in diabetes care
Tone, J. M. (2008) · Arrow@dit (Dublin Institute of Technology)
Liraglutide: ruolo nel trattamento del diabete di tipo 2
Consoli, A. (2009) · L Endocrinologo · doi:10.1007/bf03344661
Metadata
- Authors
- Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Holst, J. J.
- ORCID
- Holst, J. J.
- Venue
- Diabetologia
- Published
- 2006-01-14
- Volume
- 49
- Issue
- 2
- Pages
- 253-260
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2082032596
- Cited by
- 228
- References
- 95
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 9 · 2020: 5 · 2019: 6 · 2018: 6 · 2017: 5 · 2016: 10 · 2015: 13 · 2014: 7 · 2013: 13 · 2012: 16
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- European Foundation for the Study of Diabetes
- Medical Research Council
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- glucagon-like peptide-1, incretins, glucose-dependent insulinotropic polypeptide, proglucagon, type 2 diabetes, insulin secretion, incretin mimetics, DPP-4 inhibitors, dipeptidyl peptidase IV, HbA1c, weight loss, oral antidiabetic drugs
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Insulin Secretion, Blood Glucose, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Intestines, Peptides, Protease Inhibitors, Venoms, Receptors, Glucagon, Dipeptidyl Peptidase 4, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.